I think communicating and talking in depth about what potential issues might arise if we were to move forward with those proposed guidelines—all of that is best practice.
What you have to remember is that we didn't have any of those conversations until a request to suspend occurred, which I interpreted as a very strong suggestion, if not a demand. There was no communication directly with the minister until that point in time.
The same request had been made in December by the most vocal stakeholder—to suspend, and not to consider our concerns and reflect as a board and make a decision about whether to extend or to move forward, etc., but rather to stop the consultation altogether. The language echoed the point very closely, I would say, very closely in time on the same day that we got the letter from the minister. It's my understanding that we also received a similar request from Innovative Medicines Canada. Again it was to suspend.
It's in that context that our independence was undermined.